As User Fee Date Nears, Australia’s QRxPharma Moves To POC For MoxDuo CR Formulation; Secures Actavis As Partner
This article was originally published in PharmAsia News
The company looks to position its dual-opioid combination against Purdue Pharma’s OxyContin.
You may also be interested in...
Australia's QRxPharma Files NDA With U.S. FDA For Combo Opioid That Looks Safer Than Single Compounds
Sydney-headquartered QRxPharma filed in late July its MoxDuo IR (morphine/oxycodone) NDA with U.S. FDA for the treatment of moderate to severe acute pain. The NDA was submitted under the 505(b)(2) pathway, which allows for historical data because the two components of the dual opioid are already approved. Interestingly, the morphine and oxycodone combo appears to be safer than the two single compounds
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division
PERTH, Australia - Sydney-headquartered QRxPharma formed a development deal with China Aoxing Pharmaceutical for QRxPharma's lead candidate MoxDuo IV, an intravenous formulation of morphine and oxycodone for treating moderate to severe pain